



Form PTO/SB/08B

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Applicati n Number 09/756,978
Filing Date January 9, 2001
First Named Invent r Eugene Roussel
Gr up Art Unit 1642
Examiner Name Natalie A. Davis, Ph.D.
Attorney Docket Number 10582-1US

RECEIVED

MAY 10 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
NAD	AKBAR et al., "IFN- α and IFN- β : a link between immune memory and chronic inflammation," Immunol. Today 21(7):337-342 (2000).	
	ASSELIN-PATUREL et al., "Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and RBL of non-small cell lung cancer patients," Int. J. Cancer 77(1):7-12 (1998) (Abstract only).	
	AZAVEDO et al., "Radiological evidence of response to electrochemical treatment of breast cancer," Clin. Radiol. 43:84-87 (1991).	✓
	BAGGIOLINI et al., "Human Chemokines: an update," Annu. Rev. Immunol. 15:675-705 (1997).	
	BELLONE et al., "Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients," Am. J. Pathol. 155(2):537-547 (1999) (Abstract only).	
	BENDICH, "New data on vitamin C intake," Nutrition 13(2):154-155 (1997).	✓
	BONAGURA et al., "Recurrent respiratory papillomatosis: altered CD8(+)T-cell subsets and T(H)1/T(H)2 cytokine imbalance," Clin. Immunol. 93(3):302-311 (1999) (Abstract only).	
	CAMP et al., "In situ cytokine production by breast cancer tumor-infiltrating lymphocytes," Ann. Surg. Oncol. 3(2):176-184 (1996) (Abstract only).	
	CLIVE et al., "Mitofosine as a topical treatment for cutaneous metastases in breast carcinoma," Cancer Chemother. Pharmacol. 44 (Suppl):S29-S30 (1999).	
	COLANTONIO et al., "Upregulation of integrin $\alpha 6/\beta 1$ and chemokine receptor CCR1 by Interleukin-12 promotes the migration of human type 1 helper T cells," Blood 94(9):2981-2989 (1999).	
	CONSTANT et al., "Induction of Th1 and Th2 CD4+T cell responses: The alternative approaches," Annu. Rev. Immunol. 15:297-322 (1997).	
	DEL PRETE, "Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy," Allergy 47(5):450-455 (1992) (Abstract only).	
	DEL PRETE, "The concept of type-1 and type-2 helper T cells and their cytokines in humans" Int. Rev. Immunol. 16(3-4):427-455 (1998) (Abstract only).	
	ECHCHAKIR et al., "Analysis of T-cell-receptor β -chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas," Int. J. Cancer 81:205-213 (1999).	
	ELSASSER-BEILE et al., "Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas," Tumour Biol. 19(6):470-476 (1998) (Abstract only).	
	FLEISCHMANN et al., "Systemic effects of orally administered interferons and interleukin-2," J. Interferon Cytokine Res. 19:829-839 (1999).	
	FUJIMOTO et al., "Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state," J. Immunol. 158(12):5619-5626 (1997) (Abstract only).	
	FUJISAO et al., "Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma," Br. J. Haematol. 103(2):308-310 (1998) (Abstract only).	
	GALLUCCI et al., "Danger signals: SOS to the immune system," Curr. Op. Immunol. 13:114-119 (2001).	✓

Examiner
Signature

Natalie A. Davis

Date
Considered

6/18/02



Form PTO/SB/08B		C mplete if Kn wn		RECEIVED MAY 10 2002 TECH CENTER 1600/2900	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/756,978		
		Filing Date	January 9, 2001		
		First Named Inventor	Eugene Roussel		
		Group Art Unit	1642		
		Examiner Name	Natalie A. Davis, Ph.D.		
Sheet	2	of	5	Attorney Docket Number	10582-1US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
NAD	GHOSH et al., "Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth," J. Natl. Cancer Inst. 87(19):1478-1483 (1995) (Abstract only).	
1	GINGRAS et al., "Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue," J. Neuroimmunol. 57(1-2):143-153 (1995) (Abstract only).	
	GINGRAS et al., "Little expression of Cytokine mRNA by fresh tumor-infiltrating mononuclear leukocytes from glioma and lung adenocarcinoma," Cytokine 7(6):580-588 (1995).	
	GOEDEGEBUURE et al., "Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer," Cellular Immunol. 175:150-156 (1997).	
	GORELIK et al., "Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor," Cancer Immunol. Immunother. 39:117-126 (1994).	
	GORELIK et al., "Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome," Cancer Immunol. Immunother. 41(6):363-374 (1995) (Abstract only).	
	GOTO et al., "Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients," Cancer Immunol. Immunother. 48(8):435-442 (1999) (Abstract only).	
	INAGAWA et al., "Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions," Anticancer Res. 18(5D):3957-3964 (1998) (Abstract only).	
	ITO et al., "Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry," Cancer Immunol. Immunother. 48(4):204-208 (1999) (Abstract only).	
	JACKSON et al., "Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis," J. Urol. 159(3):1054-1063 (1998) (Abstract only).	
	KHAR et al., "High intratumoural level of cytokines mediates efficient regression of a rat histiocytoma," Clin. Exp. Immunol. 110(1):127-131 (1977).	
	KURT et al., "T lymphocytes infiltrating sites of tumor rejection and progression display identical Vβ usage but different cytotoxic activities," J. Immunol. 154(8):3969-3974 (1995).	
	LAMM, "Long-term results of intravesical therapy for superficial bladder cancer," Urol. Clin. North Am. 19(3):573-580 (1992) (Abstract only).	
	LEE et al., "T helper 2-dominant antilymphoma immune response is associated with fatal outcome," Blood 90(4):1611-1617 (1997).	
	LEIPNER et al., "Systemic enzyme therapy in oncology: effect and mode of action," Drugs 59(4):769-780 (2000) (Abstract only).	
✓	LI et al., "Effects of direct current on dog liver: possible mechanisms for tumor electrochemical treatment," Bioelectromagnetics 18:2-7 (1997).	

Examiner Signature	<i>Natalie A. Davis</i>	Date Considered	6/18/02
-----------------------	-------------------------	--------------------	---------



Form PTO/SB/08B		C mplete if Kn wn		RECEIVED MAY 10 2002 TECH CENTER 1600/2900
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Applicati n Number	09/756,978	
		Filing Date	January 9, 2001	
		First Named Invent r	Eugene Roussel	
		Gr up Art Unit	1642	
		Examiner Name	Natalie A. Davis, Ph.D.	
Sheet	3	of	5	Attorney Docket Number 10582-1US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
NAD	LI et al., "Cyclophosphamide given after active specific immunization augments antitumor immunity by modulation of Th1 commitment of CD4+ T cells," J. Surg. Oncol. 67:221-227 (1998).	✓
	LOWES et al., "T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas," J. Invest. Dermatol. 108(6):914-919 (1997).	
	LOWIN et al., "Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways," Nature 370:650-652 (1994).	
	LUCEY et al., "Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases," Clin. Microbiol. Rev. 9(4):532-562 (1996) (Abstract only).	
	MAEURER et al., "Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes," Cancer Immunol. Immunother. 41(2):111-121 (1995) (Abstract only).	
	MANTOVANI, "The chemokine system: redundancy for robust outputs," Immunol. Today 20(6):254-257 (1999).	
	MATZINGER, "An innate sense of danger," Immunology 10:399-415 (1998).	
	MOKYR et al., "Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers," Cancer Res. 49(4):870-876 (1989) (Abstract only).	
	MOSMANN et al., "Two types of murine helper T cell clone," J. Immunol. 136(7):2348-2357 (1986).	
	NEGUS et al., "Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines," Am. J. Pathol. 150(5):1723-1734 (1997) (Abstract only).	
	"New immunological paradigm, The," http://www.medcellbio.com/ accessed September 11, 2000 (14 pages).	
	OKA et al., "An immunomodulatory arabinomannan extracted from mycobacterium tuberculosis, Z-100, restores the balance of Th1/Th2 cell responses in tumor bearing mice," Immunol. Lett. 70(2):109-117 (1999) (Abstract only).	
	OKAMOTO et al., "Local injection of OK432 can augment the Th1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential," Int. J. Cancer 70:598-605 (1997).	
	ONISHI et al., "An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma," BJU Int. 83(4):488-492 (1999) (Abstract only).	
	PATARD et al., "Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review," Urol. Res. 26:155-159 (1998).	
	PELLEGRINI et al., "Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression," Cancer Immunol. Immunother. 42:1-8 (1996).	
	PETERSON et al., "Subcutaneous or oral administration of rIL-11 modulates the contact hypersensitivity response," Cytokine 12(12):1769-1777 (2000).	
✓	PRESCOTT et al., "Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms," Clin. Infect. Dis. 31(Suppl. 3):S91-S93 (2000).	✓

Examiner Signature	N. A. Davis	Date Considered	6/18/02
-------------------------------	-------------	----------------------------	---------



RECEIVED

MAY 10 2002

TECH CENTER 1600/2900

Form PTO/SB/08B		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/756,978
		Filing Date	January 9, 2001
		First Named Inventor	Eugene Roussel
		Group Art Unit	1642
		Examiner Name	Natalie A. Davis, Ph.D.
Sheet 4 of 5	Attorney Docket Number	10582-1US	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁	
✓ AD	RAYMAN, "The importance of selenium to human health," Lancet 356:233-241 (2000).	✓	
	ROMAGNANI, "Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease," Int. J. Clin. Lab. Res. 21(2):152-158 (1991) (Abstract only).		
	ROMAGNANI, "Lymphokine production by human T cells in disease states," Annu. Rev. Immunol. 12:227-257 (1994) (Abstract only).		
	ROMAGNANI, "T-cell subsets (Th1 versus Th2)," Ann. Allergy, Asthma Immunol. 85:9-18 (2000).		
	ROUSSEL et al., "High expression of adhesion molecules/activation markers with little interleukin-2, interferon γ , and tumor necrosis factor β gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma," Cancer Immunol. Immunol. 41:1-9 (1995).		
	ROUSSEL et al., "Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas," Clin. Exp. Immunol. 105:344-352 (1996).		
	ROUSSEL et al., "Transendothelial migration induces rapid expression on neutrophils of granule-release VLA6 used for tissue infiltration," J. Leukoc. Biol. 62:356-362 (1997).		
	RUBIN et al., "Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers," Cancer Immunol. Immunother. 36(1):37-44 (1993) (Abstract only).		
	RUZEK et al., "Specific decrease of Th1-like activity in mice with plasma cell tumors," Int. Immunol. 7(7):1029-1035 (1995) (Abstract only).		
	SADANAGA et al., "Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells," J. Immunother. 22(4):315-323 (1999) (Abstract only).		
	SAINT et al., "Mechanisms of action of BCG: towards a new individualized therapeutic approach," Prog. Urol. 10(6):1118-1126 (2000) (Abstract only).	✓	
	SATO et al., "Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients," Anticancer Res. 18(5D):3951-3955 (1998) (Abstract only).		
	SHANKAR et al., "Zinc and immune function: the biological basis of altered resistance to infection," Am. J. Clin. Nutr. 68(suppl):447S-463S (1998).	✓	
	SINGH et al., "The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy," Immunol. Res. 20(2):147-161 (1999) (Abstract only).		
	SPRIETSMAN, "Modern diets and diseases: NO-zinc balance. Under Th1, zinc and nitrogen monoxide (NO) collectively protect against viruses, AIDS, autoimmunity, diabetes, allergies, asthma, infectious diseases, atherosclerosis and cancer," Med. Hypotheses 53(1):6-16 (1999) (Abstract only).	✓	
	SREDNI et al., "Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101" J. Natl. Cancer Inst. 88(18):1276-1284 (Abstract only).		
	STEIN et al., "Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy," Eur. J. Med. Res. 3(4):194-202 (1998) (Abstract only).	✓	
	STEPHENS et al., "Molecular characterisation of tumour infiltrating lymphocytes in oral squamous cell carcinoma," Cancer Immunol. Immunother. 46:34-40 (1998).		
✓	STRATEN et al., "Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma," J. Clin. Invest. 98(2):279-284 (1996).		

Examiner Signature	<i>Natalie Davis</i>	Date Considered	6/18/02
--------------------	----------------------	-----------------	---------

